Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and Safety of Thermal Ablation for Solitary Low-Risk T2N0M0 Papillary Thyroid Carcinoma

  • Yu-Lin Fei (Chinese Academy of Medical Sciences & Peking Union Medical College) ;
  • Ying Wei (Department of Interventional Medicine, China–Japan Friendship Hospital) ;
  • Zhen-Long Zhao (Department of Interventional Medicine, China–Japan Friendship Hospital) ;
  • Li-Li Peng (Department of Interventional Medicine, China–Japan Friendship Hospital) ;
  • Yan Li (Department of Interventional Medicine, China–Japan Friendship Hospital) ;
  • Shi-Liang Cao (Department of Interventional Medicine, China–Japan Friendship Hospital) ;
  • Jie Wu (Department of Interventional Medicine, China–Japan Friendship Hospital) ;
  • Hui-Di Zhou (Chinese Academy of Medical Sciences & Peking Union Medical College) ;
  • Ming-An Yu (Department of Interventional Medicine, China–Japan Friendship Hospital)
  • Received : 2023.10.16
  • Accepted : 2024.05.27
  • Published : 2024.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To evaluate the efficacy and safety of thermal ablation in treating solitary low-risk T2N0M0 papillary thyroid cancer (PTC) and compare the outcomes of microwave ablation (MWA) and radiofrequency ablation (RFA). Materials and Methods: This retrospective, single center study involved 34 patients (age: 40.0 ± 13.9 years; 28 female) who had low-risk T2N0M0 PTC with a maximum diameter >2 cm and ≤4 cm and underwent MWA (n = 15) or RFA (n = 19) from November 2016 to April 2023. The primary outcomes were the cumulative rate of disease progression and delayed surgery rates. In contrast, the secondary outcomes included changes in tumor size, cumulative rate of complete tumor disappearance, and complication rates. Results: The median follow-up period was 18.0 months (interquartile range [IQR]: 9.0-40.0 months). At 12 months, the median volume reduction rate of the ablation zone was 74.2% (IQR: 53.7%-86.0%). Disease progression was noted in two patients within 1 year, including one patient with local tumor progression post-RFA and one with a new tumor post-MWA, resulting in a constant cumulative disease progression rate of 8.8% (95% confidence interval [CI]: 0%-19.8%) throughout the remaining follow-up period. Both patients were subsequently treated with additional ablation and did not require surgery. The cumulative rates of complete tumor disappearance at 1, 3, and 5 years were 4.0% (95% CI: 0%-11.4%), 26.8% (95% CI: 2.7%-44.9%), and 51.2% (95% CI: 0%-79.1%), respectively. No significant differences were observed in the disease progression (P = 0.829) or complete tumor disappearance (P = 0.633) rates between the MWA and RFA groups. Complications occurred in 14.7% (5/34) of patients presenting with transient hoarseness. RFA had a higher but not statistically significant complication rate than MWA did (21.1% [4/19] vs. 6.7% [1/15]; P = 0.355). Conclusion: Both MWA and RFA demonstrated promising short-term outcomes in terms of efficacy and safety in treating solitary low-risk T2N0M0 PTC, with no significant differences.

Keywords

Acknowledgement

We would like to thank all participants for their support in this study.

References

  1. Gimm O. Thyroid cancer. Cancer Lett 2001;163:143-156 
  2. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA 2017;317:1338-1348 
  3. Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2018;68:55-63 
  4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133 
  5. Wang TS, Sosa JA. Thyroid surgery for differentiated thyroid cancer - recent advances and future directions. Nat Rev Endocrinol 2018;14:670-683 
  6. Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022;20:925-951 
  7. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009;115:3801-3807 
  8. Pace-Asciak P, Russell JO, Tufano RP. Review: improving quality of life in patients with differentiated thyroid cancer. Front Oncol 2023;13:1032581 
  9. Lan Y, Luo Y, Zhang M, Jin Z, Xiao J, Yan L, et al. Quality of life in papillary thyroid microcarcinoma patients undergoing radiofrequency ablation or surgery: a comparative study. Front Endocrinol (Lausanne) 2020;11:249 
  10. Li Y, Huo SN, Lu NC, Peng LL, Wei Y, Zhao ZL, et al. A comparative study of quality of life in patients with papillary thyroid carcinoma undergoing microwave ablation vs. total thyroidectomy. Int J Hyperthermia 2023;40:2250935 
  11. Cho SJ, Baek JH, Chung SR, Choi YJ, Lee JH. Thermal ablation for small papillary thyroid cancer: a systematic review. Thyroid 2019;29:1774-1783 
  12. Zhao GZ, Zhang MB. Ultrasound-guided radiofrequency ablation for the treatment of papillary thyroid carcinoma: a review of the current state and future perspectives. Ultrasonography 2024;43:79-87 
  13. Wei Y, Niu WQ, Zhao ZL, Wu J, Peng LL, Li Y, et al. Microwave ablation versus surgical resection for solitary T1N0M0 papillary thyroid carcinoma. Radiology 2022;304:704-713 
  14. Yan L, Zhang M, Song Q, Luo Y. Ultrasound-guided radiofrequency ablation versus thyroid lobectomy for low-risk papillary thyroid microcarcinoma: a propensity-matched cohort study of 884 patients. Thyroid 2021;31:1662-1672 
  15. Kim HJ, Cho SJ, Baek JH. Comparison of thermal ablation and surgery for low-risk papillary thyroid microcarcinoma: a systematic review and meta-analysis. Korean J Radiol 2021;22:1730-1741 
  16. Xiao J, Zhang Y, Zhang M, Xie F, Yan L, Luo Y, et al. Ultrasonography-guided radiofrequency ablation for the treatment of T2N0M0 papillary thyroid carcinoma: a preliminary study. Int J Hyperthermia 2021;38:402-408 
  17. Chung SR, Baek JH, Choi YJ, Sung TY, Song DE, Kim TY, et al. Sonographic assessment of the extent of extrathyroidal extension in thyroid cancer. Korean J Radiol 2020;21:1187-1195 
  18. Jeon YH, Lee JY, Yoo RE, Rhim JH, Lee KH, Choi KS, et al. Validation of ultrasound and computed tomography-based risk stratification system and biopsy criteria for cervical lymph nodes in preoperative patients with thyroid cancer. Korean J Radiol 2023;24:912-923 
  19. Roh YH, Chung SR, Baek JH, Choi YJ, Sung TY, Song DE, et al. Validation of CT-based risk stratification system for lymph node metastasis in patients with thyroid cancer. Korean J Radiol 2023;24:1028-1037 
  20. Jeong SY, Chung SR, Baek JH, Choi YJ, Kim S, Sung TY, et al. Impact of additional preoperative computed tomography imaging on staging, surgery, and postsurgical survival in patients with papillary thyroid carcinoma. Korean J Radiol 2023;24:1284-1292 
  21. Kim JH, Baek JH, Lim HK, Ahn HS, Baek SM, Choi YJ, et al. 2017 thyroid radiofrequency ablation guideline: Korean Society of Thyroid Radiology. Korean J Radiol 2018;19:632-655 
  22. Ruan J, Xu X, Cai Y, Zeng H, Luo M, Zhang W, et al. A practical CEUS thyroid reporting system for thyroid nodules. Radiology 2022;305:149-159 
  23. Ha EJ, Chung SR, Na DG, Ahn HS, Chung J, Lee JY, et al. 2021 Korean thyroid imaging reporting and data system and imaging-based management of thyroid nodules: Korean Society of Thyroid Radiology consensus statement and recommendations. Korean J Radiol 2021;22:2094-2123 
  24. Mauri G, Pacella CM, Papini E, Solbiati L, Goldberg SN, Ahmed M, et al. Image-guided thyroid ablation: proposal for standardization of terminology and reporting criteria. Thyroid 2019;29:611-618 
  25. Park HS, Baek JH, Park AW, Chung SR, Choi YJ, Lee JH. Thyroid radiofrequency ablation: updates on innovative devices and techniques. Korean J Radiol 2017;18:615-623 
  26. Lim HK, Cho SJ, Baek JH, Lee KD, Son CW, Son JM, et al. US-guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma: efficacy and safety in a large population. Korean J Radiol 2019;20:1653-1661 
  27. Gambardella C, Offi C, Romano RM, De Palma M, Ruggiero R, Candela G, et al. Transcutaneous laryngeal ultrasonography: a reliable, non-invasive and inexpensive preoperative method in the evaluation of vocal cords motility-a prospective multicentric analysis on a large series and a literature review. Updates Surg 2020;72:885-892 
  28. Mauri G, Cova L, Tondolo T, Ierace T, Baroli A, Di Mauro E, et al. Percutaneous laser ablation of metastatic lymph nodes in the neck from papillary thyroid carcinoma: preliminary results. J Clin Endocrinol Metab 2013;98:E1203-E1207 
  29. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update. Radiology 2014;273:241-260 
  30. Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2003;14(9 Pt 2):S199-S202 
  31. Wang MH, Liu X, Wang Q, Zhang HW. Safety and efficacy of ultrasound-guided thermal ablation in treating T1aN0M0 and T1bN0M0 papillary thyroid carcinoma: a meta-analysis. Front Endocrinol (Lausanne) 2022;13:952113 
  32. Ito Y, Kudo T, Kihara M, Takamura Y, Kobayashi K, Miya A, et al. Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors. Endocr J 2012;59:119-125 
  33. Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SK. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol 2008;215:145-154 
  34. Zhou G, Zhang X, Xu K, Zhang B, Su R, Cai T, et al. Retrospective analysis of the efficacy and safety of ultrasound-guided radiofrequency ablation in the treatment of papillary thyroid microcarcinoma: a follow-up study of continuous postoperative surveillance and large-sample data. Int J Endocrinol 2024;2024:2704087 
  35. Cang YC, Fan FY, Liu Y, Li JM, Pang C, Xu D, et al. Efficacy of microwave ablation in the treatment of large benign thyroid nodules: a multi-center study. Eur Radiol 2024 Mar 28 [Epub]. https://doi.org/10.1007/s00330-024-10614-w 
  36. Cao S, Wang L, Wei Y, Zhao Z, Wu J, Yu M. Influence factors and nomogram for volume reduction rate in benign thyroid nodule after thermal ablation. Int J Hyperthermia 2023;40:2220562 
  37. Yan L, Li Y, Li XY, Xiao J, Tang J, Luo Y. Clinical outcomes of ultrasound-guided radiofrequency ablation for solitary T1N0M0 papillary thyroid carcinoma: a retrospective study with more than 5 years of follow-up. Cancer 2023;129:2469-2478 
  38. Zhao ZL, Wei Y, Peng LL, Li Y, Lu NC, Yu MA. Recurrent laryngeal nerve injury in thermal ablation of thyroid nodules-risk factors and cause analysis. J Clin Endocrinol Metab 2022;107:e2930-e2937 
  39. Baek JH, Lee JH, Valcavi R, Pacella CM, Rhim H, Na DG. Thermal ablation for benign thyroid nodules: radiofrequency and laser. Korean J Radiol 2011;12:525-540 
  40. Van Slycke S, Van Den Heede K, Bruggeman N, Vermeersch H, Brusselaers N. Risk factors for postoperative morbidity after thyroid surgery in a PROSPECTIVE cohort of 1500 patients. Int J Surg 2021;88:105922 
  41. Zhao ZL, Wei Y, Peng LL, Li Y, Lu NC, Wu J, et al. Upgraded hydrodissection and its safety enhancement in microwave ablation of papillary thyroid cancer: a comparative study. Int J Hyperthermia 2023;40:2202373 
  42. Xiaoyin T, Ping L, Dan C, Min D, Jiachang C, Tao W, et al. Risk assessment and hydrodissection technique for radiofrequency ablation of thyroid benign nodules. J Cancer 2018;9:3058-3066 
  43. Rossi ED, Faquin WC, Pantanowitz L. Cytologic features of aggressive variants of follicular-derived thyroid carcinoma. Cancer Cytopathol 2019;127:432-446